Personalized therapy selection: Investigation of multiple immune-checkpoints

PD1 blockade has changed the immunotherapy approach against solid tumors – prescribing patients’ monoclonal antibody-based therapy yielded positive results. However, the number of patients that benefited was small compared to expectations, and lack of attention paid to immunohistochemistry could be responsible. Understanding the tumor microenvironment with a single biomarker is not accurate enough to predict the interaction of the drug with the site of action, or to predict the effectiveness of the drug for the patient.

In this application note, industry expert, Corinne Ramos, PhD, discusses how understanding the tumor microenvironment (TME) at the biomarker level is not enough to predict the interaction of the drug with the site of action. Her study performs a deep spatial profiling of biomarkers on two baseline non-small cell lung cancer (NSCLC) tissue samples. The population of gene expression was characterized with a focus on a specific region of interest on the tissue where she could draw conclusions on the TME.

Her research walks through:

  • Immune infiltration
  • How phenotype correlates with ICI response
  • T-cell-inflamed gene-expression profiles
  • Immune suppressive pathways that reduce ICI activity
  • Tight immune checkpoint targeting.

Learn why the TME needs to be investigated at the molecular level to accurately prescribe the appropriate therapy.

Download Now

Top 8 Benefits of Mass Spectrometry Imaging Early in Drug Development

Mass spectrometry imaging (MSI) is a groundbreaking technology that provides visuals of complex biological samples to study a drug’s distribution and understand its potential toxicity. MSI can unlock crucial data and give scientists additional insights into drug discovery, diseases, and personalized medicine.

MSI is beneficial in early development and murine models across many therapeutic areas and is especially suited to oncology due to the availability of tissue. With MSI you can:

  • Speed up and optimize the drug discovery process
  • Visualize drug distribution in tissues and tissue sub-compartments
  • Analyze samples for thousands of compounds at once
  • Eliminate sensitivity and chemical alteration concerns
  • Know whether efficacy is possible based on distribution
  • Locate and identify metabolites to understand potential toxicity
  • Improve understanding of pharmacokinetics and pharmacodynamics
  • Save money and provide a competitive development edge

Download our infographic to learn more about the benefits of mass spectrometry imaging in oncology.

Download Now

BIOANALYSIS: Approaches and Techniques for Small vs. Large Molecules

Bioanalysis plays a crucial role in the evaluation of potential drug candidates and in understanding the drug’s pharmacokinetics and pharmacodynamic profile during early clinical trials. By documenting a drug’s behavior within the body, our specialists generate essential data that regulatory authorities rely on to determine whether the drug is safe for market release.

Before choosing a suitable testing technique, it’s important to understand three factors, type of molecule, unique properties of the drug, and its intended application. Regardless of the molecule size, it’s crucial to validate appropriate methods capable of measuring the drug’s concentration and bioactivity over time.

Download our infographic to learn more.

Download Now

Importing and exporting biological samples: Dos and don’ts

To ensure that your drug program’s timeline stays on track, it is crucial to follow the strict guidelines for importing and exporting biological samples. Too often, there are several mistakes with execution that could have been avoided with proper planning, coordination, and communication. These errors not only lead to frustration but also can result in:

  • Costly delays
  • Project rework
  • Logistic challenges
  • Lost, delayed, or damaged samples
  • Handling mishaps

Discover the 5 best practices and mistakes to avoid when navigating the import and export of biological samples.

Download Now

Build a bioanalytical strategy that will ensure speed and agility

In order to build a robust bioanalytical strategy for your drug discovery program, it’s crucial to collaborate with a partner who possesses both industry expertise and a track record of operational success.

Aliri by the numbers:

  • 48-hour turnarounds in discover
  • 150 biological fluids & tissues
  • 1 million samples analyzed

Our team of seasoned scientists, industry experts, program managers, and quality specialists can help you develop a successful bioanalytical strategy that will maximize the growth of your drug discovery investments. Work with us to gain access to a robust suite of mass spectrometry platforms, achieve quality data to quickly file your IND, NDA and CTA, and forecast potential roadblocks that may cause delays in your project’s timeline.

Download our factsheet to explore our offerings, platforms, compounds, regulations and more.

Download Now

The Future of Small and Large Molecule Bioanalytics—Today

In bioanalysis, the future of small and large molecules offers exciting prospects for advancements in drug discovery, diagnostics, and therapeutics. With the increase of larger substances, emerging technologies, and new analytical approaches, drug developers are faced with both new opportunities to evaluate complex substances, and new challenges to address. Therefore, it’s important to learn which bioanalysis techniques are right for your drug.

In this white paper, you’ll learn about:

  • Bioanalysis by molecular size
  • Advancements in mass spectrometry
  • Visualization and quantification of drug distribution
  • The era of spatial imaging
  • Novel technologies and adaptions

For more information about emerging technologies revolutionizing the field of bioanalysis, download our whitepaper today.

Download Now

Common Approaches to Bioanalysis of Oligonucleotides

The significance of oligonucleotides (OGNTs) in drug development is increasing rapidly, as they offer promising and life-changing treatments that can improve patients’ lives. However, the promising and vast opportunities of OGNTs come with a unique set of challenges and nuances unlike other types of molecules.

 

Within bioanalysis, there are 5 main approaches for OGNTs to consider:

  • LC/UV
  • LC/MS/MS
  • Hybridization LF/FD
  • LC/HRMS
  • Hybridization ELISA

Learn how to evaluate the pros and cons of each approach to decide what’s best for your OGNTs.

Download Now

Validating the efficacy of a compound with spatial imaging

With the ever-changing drug development landscape, pharma and biotech companies have the challenging task to quickly and efficiently generate quality and unique data to file an IND. Spatial bioanalysis is a unique solution that can help you achieve this goal, while also enabling strategic and optimized decision making throughout your process.

Download this spatial bioanalysis white paper to gain insights from industry expert, Corinne Ramos, PhD. Discussion points include:

  • Precision medicine development and added value
  • Disease heterogeneity: Why is it? Why is it important? How do we visualize it?

Target discovery and development of composite biomarkers

Download Now

Streamlining the Importing and Exporting of Biological Samples

With the evolving requirements of importing and exporting biological samples, there is a heightened priority to proactively plan, execute, and coordinate procedures. Streamlining this process can help improve logistics, ensure timely execution, and increase workflow efficiencies. Despite the complexity, importing and exporting biological samples can become a seamless and predictable phase in research and development, especially when partnering with the right bioanalytical partner.

Download this white paper to learn from industry expert Mark Vann.

Download Now

Non-proprietary Assays

There are many factors to consider when choosing a bioanalysis partner for your project. One of which should be finding a company with the scientific expertise and resources you need to move forward with speed, accuracy, and certainty. One of those resources being a large assortment of assays.

Aliri has over 1500 non-proprietary assays that allow us to measure a wide variety of compounds using our advanced technology. Our expertise will advance your molecule with speed and agility!

Our species matrices include:

  • Human Plasma
  • Human Serum
  • Human Whole Blood
  • Whole Blood
  • Human Dried Blood Spot
  • Human Urine

Most common Assays:

  • Budesonide
  • Bupropion, Hydroxybupropion
  • Diclofenac
  • Naloxone
  • Naltrexone/ Naltrexol
  • Pregabalin
  • Riluzole
  • Rosuvastatin
  • Rosuvastatin/ Desmethyl Rosuvastatin/ Rosuvastatine Lactone
  • Tenofovir
  • Tiotropium

Download our latest comprehensive list of non-proprietary assays available for you.

Download Now